{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T18:50:32Z","timestamp":1795027832820,"version":"4.10.2"},"reference-count":239,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T00:00:00Z","timestamp":1570665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Methotrexate (MTX) is the first line drug for the treatment of a number of rheumatic and non-rheumatic disorders. It is currently used as an anchor disease, modifying anti-rheumatic drug in the treatment of rheumatoid arthritis (RA). Despite the development of numerous new targeted therapies, MTX remains the backbone of RA therapy due to its potent efficacy and tolerability. There has been also a growing interest in the use of MTX in the treatment of chronic viral mediated arthritis. Many viruses\u2014including old world alphaviruses, Parvovirus B19, hepatitis B\/C virus, and human immunodeficiency virus\u2014have been associated with arthritogenic diseases and reminiscent of RA. MTX may provide benefits although with the potential risk of attenuating patients\u2019 immune surveillance capacities. In this review, we describe the emerging mechanisms of action of MTX as an anti-inflammatory drug and complementing its well-established immunomodulatory activity. The mechanisms involve adenosine signaling modulation, alteration of cytokine networks, generation of reactive oxygen species and HMGB1 alarmin suppression. We also provide a comprehensive understanding of the mechanisms of MTX toxic effects. Lastly, we discussed the efficacy, as well as the safety, of MTX used in the management of viral-related rheumatic syndromes.<\/jats:p>","DOI":"10.3390\/ijms20205023","type":"journal-article","created":{"date-parts":[[2019,10,11]],"date-time":"2019-10-11T03:07:11Z","timestamp":1570763231000},"page":"5023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":436,"title":["Methotrexate an Old Drug with New Tricks"],"prefix":"10.3390","volume":"20","author":[{"given":"Yosra","family":"Bedoui","sequence":"first","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM U1187, CNRS 9192, IRD 249, Universit\u00e9 de La R\u00e9union\u2014Plateforme Technologique CYROI\u20142, rue Maxime Rivi\u00e8re, 97490 Sainte-Clotilde, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Guillot","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie, CHU La R\u00e9union site F\u00e9lix Guyon, All\u00e9e des Topazes, CS11021, 97400 Saint Denis de La R\u00e9union, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"S\u00e9lambarom","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM U1187, CNRS 9192, IRD 249, Universit\u00e9 de La R\u00e9union\u2014Plateforme Technologique CYROI\u20142, rue Maxime Rivi\u00e8re, 97490 Sainte-Clotilde, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Guiraud","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM U1187, CNRS 9192, IRD 249, Universit\u00e9 de La R\u00e9union\u2014Plateforme Technologique CYROI\u20142, rue Maxime Rivi\u00e8re, 97490 Sainte-Clotilde, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4286-0063","authenticated-orcid":false,"given":"Claude","family":"Giry","sequence":"additional","affiliation":[{"name":"Laboratoire de biologie, CNR associ\u00e9 des arbovirus, CHU La R\u00e9union site F\u00e9lix Guyon, All\u00e9e des Topazes, CS11021, 97400 Saint Denis de La R\u00e9union, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Christine","family":"Jaffar-Bandjee","sequence":"additional","affiliation":[{"name":"Laboratoire de biologie, CNR associ\u00e9 des arbovirus, CHU La R\u00e9union site F\u00e9lix Guyon, All\u00e9e des Topazes, CS11021, 97400 Saint Denis de La R\u00e9union, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Ralandison","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie\u2014M\u00e9decine Interne, CHU Morafeno, Route d\u2019Ivoloina 501, Toamasina, Madagascar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Gasque","sequence":"additional","affiliation":[{"name":"Unit\u00e9 Mixte de Recherche Processus Infectieux en Milieu Insulaire Tropical (PIMIT), INSERM U1187, CNRS 9192, IRD 249, Universit\u00e9 de La R\u00e9union\u2014Plateforme Technologique CYROI\u20142, rue Maxime Rivi\u00e8re, 97490 Sainte-Clotilde, France"},{"name":"P\u00f4le de Biologie, secteur Laboratoire d\u2019Immunologie Clinique et Exp\u00e9rimentale de la zone de l\u2019Oc\u00e9an Indien (LICE-OI), CHU La R\u00e9union site F\u00e9lix Guyon, All\u00e9e des Topazes, CS11021, 97400 Saint Denis de La R\u00e9union, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,10,10]]},"reference":[{"key":"ref_1","first-page":"S5","article-title":"Mechanisms of action of methotrexate","volume":"71","author":"Chan","year":"2013","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nrrheum.2010.5","article-title":"Methotrexate\u2014How does it really work?","volume":"6","author":"Chan","year":"2010","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0162-3109(00)00189-2","article-title":"Mechanisms of action of methotrexate","volume":"47","author":"Genestier","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/BOR.0000000000000486","article-title":"Emergence and treatment of chikungunya arthritis","volume":"30","author":"Sutaria","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7861\/clinmedicine.16-2-129","article-title":"Viral arthritis","volume":"16","author":"Marks","year":"2016","journal-title":"Clin. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1136\/ard.58.8.454","article-title":"Mechanisms of viral pathogenesis in rheumatic disease","volume":"58","author":"Perl","year":"1999","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nrrheum.2012.64","article-title":"Arthritogenic alphaviruses\u2014An overview","volume":"8","author":"Suhrbier","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.4254\/wjh.v9.i26.1092","article-title":"Risk of liver disease in methotrexate treated patients","volume":"9","author":"Conway","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_9","unstructured":"WHO (2019, July 22). WHO Model Lists of Essential Medicines 21th List. Available online: http:\/\/www.who.int\/medicines\/publications\/essentialmedicines\/en\/."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jbspin.2009.05.007","article-title":"Methotrexate: Still the anchor drug in RA treatment","volume":"76","author":"Bijlsma","year":"2009","journal-title":"Jt. Bone Spine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 Update of the 2008 American College of Rheumatology (ACR) Recommendations for the use of Disease-Modifying Anti-Rheumatic Drugs and Biologics in the treatment of Rheumatoid Arthritis (RA)","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2013-203485","article-title":"Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis","volume":"72","author":"Emery","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1124\/pr.57.2.3","article-title":"Low-dose methotrexate: A mainstay in the treatment of rheumatoid arthritis","volume":"57","author":"Cronstein","year":"2005","journal-title":"Pharmacol. Rev."},{"key":"ref_14","first-page":"168","article-title":"Understanding the mechanisms of action of methotrexate: Implications for the treatment of rheumatoid arthritis","volume":"65","author":"Tian","year":"2007","journal-title":"Bull. NYU Hosp. Jt. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1365-2133.2008.08876.x","article-title":"Effect of folic or folinic acid supplementation on methotrexate-associated safety and efficacy in inflammatory disease: A systematic review","volume":"160","author":"Prey","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/0049-0172(94)90027-2","article-title":"Low-dose methotrexate in rheumatic diseases\u2014Efficacy, side effects, and risk factors for side effects","volume":"23","author":"Schnabel","year":"1994","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s12026-014-8564-6","article-title":"Three decades of low-dose methotrexate in rheumatoid arthritis: Can we predict toxicity?","volume":"60","author":"Lima","year":"2014","journal-title":"Immunol. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1021\/ja01173a061","article-title":"Analogs of Pteroylglutamic Acid. III. 4-Amino Derivatives","volume":"71","author":"Seeger","year":"1949","journal-title":"J. Am. Chem. Soc."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/1097-0142(194909)2:5<877::AID-CNCR2820020520>3.0.CO;2-0","article-title":"Bone-marrow changes in man after treatment with aminopterin, amethopterin, and aminoanfol. With special reference to megaloblastosis and tumor remission","volume":"2","author":"Thiersch","year":"1949","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/jid.1952.100","article-title":"Comparative Effects of Aminopterin, Cortisone and Acth in Experimental Formaldehyde Arthritis and Psoriatic Arthritis","volume":"19","author":"Gubner","year":"1952","journal-title":"J. Investig. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/00000441-195102000-00009","article-title":"Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis","volume":"221","author":"Gubner","year":"1951","journal-title":"Am. J. Med. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of Low-Dose Methotrexate in Rheumatoid Arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/BOR.0b013e328329c79d","article-title":"An update on methotrexate","volume":"21","author":"Braun","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2165\/00003495-199447010-00003","article-title":"Methotrexate in rheumatoid arthritis. An update","volume":"47","author":"Bannwarth","year":"1994","journal-title":"Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.clinthera.2011.05.044","article-title":"The Use of Biologics in Rheumatoid Arthritis: Current and Emerging Paradigms of Care","volume":"33","author":"Curtis","year":"2011","journal-title":"Clin. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/jm9605288","article-title":"Antirheumatic Agents: Novel Methotrexate Derivatives Bearing a Benzoxazine or Benzothiazine Moiety","volume":"40","author":"Matsuoka","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.1021\/jm970085n","article-title":"Synthesis and evaluation of novel fluorinated methotrexate derivatives for application to rheumatoid arthritis treatment","volume":"40","author":"Kokuryo","year":"1997","journal-title":"J. Med. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.6061\/clinics\/2016(01)09","article-title":"Anti-inflammatory effects of intravenous methotrexate associated with lipid nanoemulsions on antigen-induced arthritis","volume":"71","author":"Mello","year":"2016","journal-title":"Clinics"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tamura, T., Higuchi, Y., Kitamura, H., Murao, N., Saitoh, R., Morikawa, T., and Sato, H. (2016). Novel hyaluronic acid-methotrexate conjugate suppresses joint inflammation in the rat knee: Efficacy and safety evaluation in two rat arthritis models. Arthritis Res. Ther., 18.","DOI":"10.1186\/s13075-016-0971-8"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular Basis for Pharmacokinetics and Pharmacodynamics of Methotrexate in Rheumatoid Arthritis Therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: A systematic review of the literature","volume":"68","author":"Visser","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/OARRR.S131668","article-title":"Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis","volume":"9","author":"Bello","year":"2017","journal-title":"Open Access Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.4161\/cbt.22020","article-title":"The human proton-coupled folate transporter: Biology and therapeutic applications to cancer","volume":"13","author":"Desmoulin","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00003088-200342020-00003","article-title":"Pharmacokinetics and pharmacodynamics of methotrexate in non-neoplastic diseases","volume":"42","author":"Grim","year":"2003","journal-title":"Clin. Pharm."},{"key":"ref_38","first-page":"645","article-title":"Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis","volume":"31","author":"Hoekstra","year":"2004","journal-title":"J. Rheumatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: Drug-exposure limitations of oral methotrexate at doses \u226515 mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0889-857X(05)70359-8","article-title":"Pharmacology and pharmacokinetics of methotrexate in rheumatic disease. Practical issues in treatment and design","volume":"23","author":"Hillson","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s12325-016-0295-8","article-title":"Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration","volume":"33","author":"Bianchi","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0160-5402(81)90088-7","article-title":"Protein binding of methotrexate in sera from normal human beings: Effect of drug concentration, pH, temperature, and storage","volume":"5","author":"Paxton","year":"1981","journal-title":"J. Pharmacol. Methods"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/jps.2600780219","article-title":"Pharmacokinetics of Low-Dose Methotrexate in Rheumatoid Arthritis Patients","volume":"78","author":"Herman","year":"1989","journal-title":"J. Pharm. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2125.1994.tb05713.x","article-title":"Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis","volume":"37","author":"Tracy","year":"1994","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2165\/00003088-199630030-00002","article-title":"Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis","volume":"30","author":"Bannwarth","year":"1996","journal-title":"Clin. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2125.1993.tb04158.x","article-title":"The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis","volume":"35","author":"Seideman","year":"1993","journal-title":"Br. J. Clin. Pharm."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.1780330620","article-title":"Biliary elimination of low-dose methotrexate in humans","volume":"33","author":"Nuernberg","year":"1990","journal-title":"Arthritis Rheum."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.57.2.110","article-title":"Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients","volume":"57","author":"Bressolle","year":"1998","journal-title":"Ann. Rheum. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/0190-9622(91)70199-C","article-title":"The pharmacology of methotrexate","volume":"25","author":"Olsen","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_50","first-page":"S40","article-title":"Methotrexate transport mechanisms: The basis for targeted drug delivery and \u00df-folate-receptor-specific treatment","volume":"28","author":"Fiehn","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","article-title":"Polyglutamation of methotrexate. Is methotrexate a prodrug?","volume":"76","author":"Chabner","year":"1985","journal-title":"J. Clin. Investig."},{"key":"ref_52","first-page":"2423","article-title":"Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of \u03b3-Glutamyl Hydrolase Activity","volume":"8","author":"Panetta","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Brown, P.M., Pratt, A.G., and Isaacs, J.D. (2016). Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat. Rev. Rheumatol., 12.","DOI":"10.1038\/nrrheum.2016.175"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.3390\/ph5080802","article-title":"Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics","volume":"5","author":"Murakami","year":"2012","journal-title":"Pharmaceuticals"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1002\/art.24653","article-title":"Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment","volume":"60","author":"Stamp","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1136\/ard.2004.033399","article-title":"Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: Results of a multicentred cross sectional observational study","volume":"64","author":"Dervieux","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj3420143","article-title":"Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: A metabolic basis for efficacy in rheumatoid arthritis?","volume":"342","author":"Fairbanks","year":"1999","journal-title":"Biochem. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1172\/JCI2676","article-title":"Immunosuppressive properties of methotrexate: Apoptosis and clonal deletion of activated peripheral T cells","volume":"102","author":"Genestier","year":"1998","journal-title":"J. Clin. Investig."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1136\/ard.55.4.237","article-title":"Divergent effects of methotrexate on the clonal growth of T and B lymphocytes and synovial adherent cells from patients with rheumatoid arthritis","volume":"55","author":"Nakajima","year":"1996","journal-title":"Ann. Rheum. Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"833","DOI":"10.7326\/0003-4819-121-11-199412010-00002","article-title":"Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial","volume":"121","author":"Morgan","year":"1994","journal-title":"Ann. Intern. Med."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Cronstein, B.N., and Hask\u00f3, G. (2013). Regulation of Inflammation by Adenosine. Front. Immunol., 4.","DOI":"10.3389\/fimmu.2013.00085"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.it.2003.11.003","article-title":"Adenosine: An endogenous regulator of innate immunity","volume":"25","author":"Cronstein","year":"2004","journal-title":"Trends Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Stamp, L.K., Hazlett, J., Roberts, R.L., Frampton, C., Highton, J., and Hessian, P.A. (2012). Adenosine receptor expression in rheumatoid synovium: A basis for methotrexate action. Arthritis Res. Ther., 14.","DOI":"10.1186\/ar3871"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrrheum.2016.178","article-title":"Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases","volume":"13","author":"Cronstein","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_65","first-page":"89","article-title":"Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis","volume":"23","author":"Forrest","year":"2005","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Varani, K., Padovan, M., Vincenzi, F., Targa, M., Trotta, F., Govoni, M., and Borea, P.A. (2011). A2A and A3 adenosine receptor expression in rheumatoid arthritis: Upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. Arthritis Res., 13.","DOI":"10.1186\/ar3527"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/bj2360193","article-title":"Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5\u2032-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide","volume":"236","author":"Baggott","year":"1986","journal-title":"Biochem. J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/art.22643","article-title":"The antiinflammatory mechanism of methotrexate depends on extracellular conversion of adenine nucleotides to adenosine by ecto-5\u2032-nucleotidase: Findings in a study of ecto-5\u2032-nucleotidase gene-deficient mice","volume":"56","author":"Montesinos","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1073\/pnas.88.6.2441","article-title":"Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells","volume":"88","author":"Cronstein","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Cronstein, B.N., Naime, D., and Ostad, E. (1993). The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J. Clin. Investig., 92.","DOI":"10.1172\/JCI116884"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/art.10712","article-title":"Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68","volume":"48","author":"Montesinos","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Montesinos, M.C., Desai, A., and Cronstein, B.N. (2006). Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res., 8.","DOI":"10.1186\/ar1914"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1136\/ard.2005.048637","article-title":"Methotrexate modulates the kinetics of adenosine in humans in vivo","volume":"65","author":"Riksen","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/1529-0131(200003)43:3<656::AID-ANR23>3.0.CO;2-H","article-title":"Reversal of the antiinflammatory effects of methotrexate by the nonselective adenosine receptor antagonists theophylline and caffeine: Evidence that the antiinflammatory effects of methotrexate are mediated via multiple adenosine receptors in rat adjuvant arthritis","volume":"43","author":"Montesinos","year":"2000","journal-title":"Arthritis Rheum."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.10766","article-title":"Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis","volume":"48","author":"Nesher","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_76","first-page":"1275","article-title":"Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis","volume":"33","author":"Heller","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_77","first-page":"689","article-title":"Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis","volume":"19","author":"Yukioka","year":"1992","journal-title":"J. Rheumatol."},{"key":"ref_78","first-page":"395","article-title":"In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients","volume":"14","author":"Nesher","year":"1996","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_79","first-page":"1","article-title":"Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism","volume":"13","author":"Smith","year":"1991","journal-title":"Int. J. Tissue React."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00011-005-1355-8","article-title":"Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines","volume":"54","author":"Herman","year":"2005","journal-title":"Inflamm. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.bjp.0705054","article-title":"The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species","volume":"138","author":"Phillips","year":"2003","journal-title":"Br. J. Pharm."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.1073\/pnas.0409594102","article-title":"Endothelial dihydrofolate reductase: Critical for nitric oxide bioavailability and role in angiotensin II uncoupling of endothelial nitric oxide synthase","volume":"102","author":"Chalupsky","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.freeradbiomed.2011.03.010","article-title":"Dihydrofolate reductase protects endothelial nitric oxide synthase from uncoupling in tetrahydrobiopterin deficiency","volume":"50","author":"Crabtree","year":"2011","journal-title":"Free Radic. Biol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/keu279","article-title":"Methotrexate-mediated inhibition of nuclear factor \u03baB activation by distinct pathways in T cells and fibroblast-like synoviocytes","volume":"54","author":"Spurlock","year":"2015","journal-title":"Rheumatology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0162-3109(99)00185-X","article-title":"Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis","volume":"47","author":"Sung","year":"2000","journal-title":"Immunopharmacology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/ar302","article-title":"A follow-up to \u201cAnti-cytokine therapy in chronic destructive arthritis\u201d by Wim B van den Berg","volume":"3","author":"Brennan","year":"2001","journal-title":"Arthritis Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1093\/rheumatology\/37.5.502","article-title":"Methotrexate reduces inflammatory cell numbers, expression of monokines and of adhesion molecules in synovial tissue of patients with rheumatoid arthritis","volume":"37","author":"Dolhain","year":"1998","journal-title":"Br. J. Rheumatol."},{"key":"ref_88","first-page":"667","article-title":"Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin 1 beta to the interleukin 1 receptor on target cells","volume":"31","author":"Brody","year":"1993","journal-title":"Eur. J. Clin. Chem. Clin. Biochem."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Neurath, M.F., Hildner, K., Becker, C., Schlaak, J.F., Barbulescu, K., Germann, T., Schmitt, E., Schirmacher, P., Haralambous, S., and Pasparakis, M. (1999). Methotrexate specifically modulates cytokine production by T cells and macrophages in murine collagen-induced arthritis (CIA): A mechanism for methotrexate-mediated immunosuppression. Clin. Exp. Immunol., 115.","DOI":"10.1046\/j.1365-2249.1999.00753.x"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2249.1999.01022.x","article-title":"Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis","volume":"118","author":"Hildner","year":"1999","journal-title":"Clin. Exp. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/ard.59.4.311","article-title":"Response to methotrexate in early rheumatoid arthritis is associated with a decrease of T cell derived tumour necrosis factor \u03b1, increase of interleukin 10, and predicted by the initial concentration of interleukin 4","volume":"59","author":"Rudwaleit","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1093\/rheumatology\/keg323","article-title":"Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis","volume":"42","author":"Gerards","year":"2003","journal-title":"Rheumatology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.4049\/jimmunol.173.2.1463","article-title":"IL-15 and the initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in rheumatoid arthritis: Effect of methotrexate","volume":"173","author":"Balsa","year":"2004","journal-title":"J. Immunol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/1529-0131(199801)41:1<48::AID-ART7>3.0.CO;2-K","article-title":"Antiinflammatory and immunoregulatory action of methotrexate in the treatment of rheumatoid arthritis: Evidence of increased interleukin-4 and interleukin-10 gene expression demonstrated in vitro by competitive reverse transcriptase-polymerase chain reaction","volume":"41","author":"Constantin","year":"1998","journal-title":"Arthritis Rheum."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard.60.8.729","article-title":"Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis","volume":"60","author":"Cutolo","year":"2001","journal-title":"Ann. Rheum. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/anr.1780320403","article-title":"The effects of methotrexate on the production and activity of interleukin-1","volume":"32","author":"Segal","year":"1989","journal-title":"Arthritis Rheum."},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Bergstr\u00f6m, B., Carlsten, H., and Ekwall, A.K.H. (2018). Methotrexate inhibits effects of platelet-derived growth factor and interleukin-1\u03b2 on rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Res., 20.","DOI":"10.1186\/s13075-018-1554-7"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.1780400104","article-title":"Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis?","volume":"40","author":"Burmester","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1093\/rheumatology\/keh583","article-title":"Downregulation of activating Fc\u03b3 receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment","volume":"44","author":"Wijngaarden","year":"2005","journal-title":"Rheumatology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1186\/ar572","article-title":"Matrix metalloproteinases in arthritic disease","volume":"4","author":"Murphy","year":"2002","journal-title":"Arthritis Res. Ther."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/art.1780370802","article-title":"Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?","volume":"37","author":"Vincenti","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_102","first-page":"1523","article-title":"Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis","volume":"33","author":"Fiedorczyk","year":"2006","journal-title":"J. Rheumatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1046\/j.1365-2249.2003.02192.x","article-title":"Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis","volume":"133","author":"Ho","year":"2003","journal-title":"Clin. Exp. Immunol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/rheumatology\/39.6.637","article-title":"Enhanced production of tissue inhibitor of metalloproteinases by peripheral blood mononuclear cells of rheumatoid arthritis patients responding to methotrexate treatment","volume":"39","author":"Seitz","year":"2000","journal-title":"Rheumatology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/art.1780370207","article-title":"Mechanisms of Methotrexate Action in Rheumatoid Arthritis","volume":"37","author":"Firestein","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_106","first-page":"5258","article-title":"Combined effects of tumor necrosis factor-\u03b1 and interleukin-1\u03b2 on lysyl oxidase and matrix metalloproteinase expression in human knee synovial fibroblasts in vitro","volume":"14","author":"Zhang","year":"2017","journal-title":"Exp. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4049\/jimmunol.167.1.469","article-title":"Microsomal Prostaglandin E Synthase is Regulated by Proinflammatory Cytokines and Glucocorticoids in Primary Rheumatoid Synovial Cells","volume":"167","author":"Stichtenoth","year":"2001","journal-title":"J. Immunol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1002\/art.20286","article-title":"Expression of microsomal prostaglandin E synthase 1 in rheumatoid arthritis synovium","volume":"50","author":"Westman","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.colsurfb.2016.07.046","article-title":"Effective transdermal delivery of methotrexate through nanostructured lipid carriers in an experimentally induced arthritis model","volume":"147","author":"Garg","year":"2016","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_110","first-page":"2092","article-title":"Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits","volume":"23","author":"Novaes","year":"1996","journal-title":"J. Rheumatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s000110050575","article-title":"The suppression of rat collagen-induced arthritis and inhibition of macrophage derived mediator release by liposomal methotrexate formulations","volume":"49","author":"Williams","year":"2000","journal-title":"Inflamm. Res."},{"key":"ref_112","first-page":"433","article-title":"Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes","volume":"25","author":"Vergne","year":"1998","journal-title":"J. Rheumatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/rheumatology\/39.5.533","article-title":"Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis","volume":"39","author":"Mello","year":"2000","journal-title":"Rheumatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/art.1780310301","article-title":"Methotrexate in rheumatoid arthritis","volume":"31","author":"Furst","year":"1988","journal-title":"Arthritis Rheum."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"Gheorghe, K.R., Sadique, S., Leclerc, P., Idborg, H., Wobst, I., Catrina, A.I., Jakobsson, P.-J., and Korotkova, M. (2012). Limited effect of anti-rheumatic treatment on 15-prostaglandin dehydrogenase in rheumatoid arthritis synovial tissue. Arthritis Res., 14.","DOI":"10.1186\/ar3851"},{"key":"ref_116","first-page":"65","article-title":"An investigation of cell proliferation and soluble mediators induced by interleukin 1\u03b2 in human synovial fibroblasts: Comparative response in osteoarthritis and rheumatoid arthritis","volume":"50","author":"Inoue","year":"2001","journal-title":"Inflamm. Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1600-065X.2012.01102.x","article-title":"It takes two to tango: I\u03baBs, the multifunctional partners of NF-\u03baB","volume":"246","author":"Hinz","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/j.1365-2796.2008.01953.x","article-title":"NF-\u03baB in inflammatory bowel disease","volume":"263","author":"Atreya","year":"2008","journal-title":"J. Intern. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1172\/JCI11830","article-title":"NF-\u03baB: A key role in inflammatory diseases","volume":"107","author":"Tak","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/ar300","article-title":"NF-kappaB in rheumatoid arthritis: A pivotal regulator of inflammation, hyperplasia, and tissue destruction","volume":"3","author":"Makarov","year":"2001","journal-title":"Arthritis Res."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1096\/fj.10-160549","article-title":"p53 and NF-\u03baB: Different strategies for responding to stress lead to a functional antagonism","volume":"24","author":"Ak","year":"2010","journal-title":"FASEB J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/ard.2003.007401","article-title":"p53 in rheumatoid arthritis synovial fibroblasts at sites of invasion","volume":"62","author":"Seemayer","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1002\/art.20468","article-title":"NF-\u03baB: Holy Grail for rheumatoid arthritis?","volume":"50","author":"Firestein","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1002\/art.38805","article-title":"Methotrexate inhibits NF-\u03baB activity via lincRNA-p21 induction","volume":"66","author":"Spurlock","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.immuni.2012.03.014","article-title":"JAK and STAT Signaling Molecules in Immunoregulation and Immune-Mediated Disease","volume":"36","author":"Plenge","year":"2012","journal-title":"Immunity"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1002\/art.11095","article-title":"The JAK\/STAT pathway in rheumatoid arthritis: Pathogenic or protective?","volume":"48","author":"Ivashkiv","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1517\/13543784.2012.690029","article-title":"JAK inhibition for the treatment of rheumatoid arthritis: A new era in oral DMARD therapy","volume":"21","author":"Vaddi","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Thomas, S., Fisher, K.H., Snowden, J.A., Danson, S.J., Brown, S., and Zeidler, M.P. (2015). Methotrexate is a JAK\/STAT Pathway Inhibitor. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0130078"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Thomas, S.J., Fisher, K., Brown, S., Snowden, J.A., Danson, S., and Zeidler, M. (2014). Methotrexate Is a Suppressor of JAK\/STAT Pathway Activation Which Inhibits JAK2V617F Induced Signalling. Blood, 124.","DOI":"10.1182\/blood.V124.21.4577.4577"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"476","DOI":"10.2119\/2008-00034.Klune","article-title":"HMGB1: Endogenous Danger Signaling","volume":"14","author":"Klune","year":"2008","journal-title":"Mol. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00441-010-1033-1","article-title":"High-mobility group box 1 (HMGB1) as a master regulator of innate immunity","volume":"343","author":"Castiglioni","year":"2011","journal-title":"Cell Tissue Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature00858","article-title":"Release of chromatin protein HMGB1 by necrotic cells triggers inflammation","volume":"418","author":"Scaffidi","year":"2002","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI200114002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1196\/annals.1333.077","article-title":"Advanced glycation end product receptor-mediated cellular dysfunction","volume":"1043","author":"Bierhaus","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/rheumatology\/ket134","article-title":"The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis","volume":"52","author":"Chen","year":"2013","journal-title":"Rheumatology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1002\/art.10540","article-title":"High mobility group box chromosomal protein 1: A novel proinflammatory mediator in synovitis","volume":"46","author":"Kokkola","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.10859","article-title":"High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine","volume":"48","author":"Taniguchi","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1002\/art.11028","article-title":"High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis","volume":"48","author":"Pullerits","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1002\/art.11161","article-title":"Successful treatment of collagen-induced arthritis in mice and rats by targeting extracellular high mobility group box chromosomal protein 1 activity","volume":"48","author":"Kokkola","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11010-016-2783-1","article-title":"Methotrexate affects HMGB1 expression in rheumatoid arthritis, and the downregulation of HMGB1 prevents rheumatoid arthritis progression","volume":"420","author":"Li","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Kuroiwa, Y., Takakusagi, Y., Kusayanagi, T., Kuramochi, K., Imai, T., Hirayama, T., Ito, I., Yoshida, M., Sakaguchi, K., and Sugawara, F. (2013). Identification and Characterization of the Direct Interaction between Methotrexate (MTX) and High-Mobility Group Box 1 (HMGB1) Protein. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0063073"},{"key":"ref_142","first-page":"S46","article-title":"Optimal administration and dosage of methotrexate","volume":"28","author":"Braun","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0049-0172(98)80049-8","article-title":"Methotrexate in rheumatoid arthritis: An updatewith focus on mechanisms involved in toxicity","volume":"27","author":"Laan","year":"1998","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00280-012-2062-0","article-title":"A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis","volume":"71","author":"Abolmaali","year":"2013","journal-title":"Cancer Chemother. Pharm."},{"key":"ref_145","first-page":"272","article-title":"Outcomes Related to Methotrexate Dose and Route of Administration in Patients with Rheumatoid Arthritis: A Systematic Literature Review","volume":"33","author":"Goodman","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2014.927817","article-title":"Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?","volume":"26","author":"Kromann","year":"2015","journal-title":"J. Dermatol. Treat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.semarthrit.2015.11.004","article-title":"Subcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: A systematic review and meta-analysis","volume":"45","author":"Li","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"Paul, M., Hemshekhar, M., Thushara, R.M., Sundaram, M.S., NaveenKumar, S.K., Naveen, S., Devaraja, S., Somyajit, K., West, R., and Nayaka, S.C. (2015). Methotrexate Promotes Platelet Apoptosis via JNK-Mediated Mitochondrial Damage: Alleviation by N-Acetylcysteine and N-Acetylcysteine Amide. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127558"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1002\/art.1780290703","article-title":"Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/sj.bjp.0706812","article-title":"Adenosine A2A receptors play a role in the pathogenesis of hepatic cirrhosis","volume":"148","author":"Chan","year":"2006","journal-title":"Br. J. Pharm."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1124\/mol.107.038760","article-title":"Adenosine A2A Receptor Occupancy Stimulates Collagen Expression by Hepatic Stellate Cells via Pathways Involving Protein Kinase A, Src, and Extracellular Signal-Regulated Kinases 1\/2 Signaling Cascade or p38 Mitogen-Activated Protein Kinase Signaling Pathway","volume":"72","author":"Che","year":"2007","journal-title":"Mol. Pharm."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrrheum.2010.214","article-title":"Hepatotoxicity related to antirheumatic drugs","volume":"7","author":"Aithal","year":"2011","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/1751-2980.12612","article-title":"Chronic liver injury induced by drugs and toxins","volume":"19","author":"Andrade","year":"2018","journal-title":"J. Dig. Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1177\/0192623310367806","article-title":"Protective Effect of \u03b2-Carotene on Methotrexate\u2013Induced Oxidative Liver Damage","volume":"38","author":"Vardi","year":"2010","journal-title":"Toxicol. Pathol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.tox.2008.11.016","article-title":"Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway","volume":"256","author":"Kim","year":"2009","journal-title":"Toxicology"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1164\/ajrccm.155.2.9032171","article-title":"Immunosuppressive and cytotoxic pharmacotherapy for pulmonary disorders","volume":"155","author":"Lynch","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/BF02238967","article-title":"Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: Report of five cases and review of the literature","volume":"16","author":"Salaffi","year":"1997","journal-title":"Clin. Rheumatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1517\/14740338.4.4.723","article-title":"Methotrexate pulmonary toxicity","volume":"4","author":"Lateef","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2131\/jts.35.653","article-title":"Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro","volume":"35","author":"Ohbayashi","year":"2010","journal-title":"J. Toxicol. Sci."},{"key":"ref_161","first-page":"1043","article-title":"The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis","volume":"22","author":"Golden","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/ard.2008.106617","article-title":"Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: The CAMERA study","volume":"69","author":"Verstappen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_163","first-page":"38","article-title":"Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: Association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy","volume":"22","author":"Kremer","year":"1995","journal-title":"J. Rheumatol."},{"key":"ref_164","first-page":"1126","article-title":"Renal effects of low dose methotrexate in rheumatoid arthritis","volume":"20","author":"Seideman","year":"1993","journal-title":"J. Rheumatol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"JCO"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1002\/pbc.20471","article-title":"Methotrexate induces cell swelling and necrosis in renal tubular cells","volume":"46","author":"Chen","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0889-857X(05)70358-6","article-title":"The mechanism of action of methotrexate","volume":"23","author":"Cronstein","year":"1997","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Li, X., Abe, E., Yamakawa, Y., Yoneda, G., Fujino, R., Yamashita, M., Iida, Y., Jono, H., and Saito, H. (2016). Effect of Administration Duration of Low Dose Methotrexate on Development of Acute Kidney Injury in Rats. J. Kidney.","DOI":"10.4172\/2472-1220.1000130"},{"key":"ref_169","first-page":"1308","article-title":"Adenosine A1 receptor promotion of multinucleated giant cell formation by human monocytes: A mechanism for methotrexate-induced nodulosis in rheumatoid arthritis","volume":"40","author":"Merrill","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_170","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.neuroscience.2008.01.017","article-title":"Adenosine and the homeostatic control of sleep: Effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness","volume":"153","author":"Thakkar","year":"2008","journal-title":"Neuroscience"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0140-6736(95)90464-6","article-title":"Aminophylline for methotrexate-induced neurotoxicity","volume":"345","author":"Bernini","year":"1995","journal-title":"Lancet"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1200\/JCO.1997.15.8.2800","article-title":"Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer","volume":"15","author":"Quinn","year":"1997","journal-title":"J. Clin. Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1203\/00006450-199502000-00004","article-title":"Changes of Cerebral Biopterin and Biogenic Amine Metabolism in Leukemic Children Receiving 5 g\/m2 Intravenous Methotrexate","volume":"37","author":"Millot","year":"1995","journal-title":"Pediatric Res."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/art.1780400527","article-title":"Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother","volume":"40","author":"Buckley","year":"1997","journal-title":"Arthritis Rheum."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/art.1780370208","article-title":"The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats","volume":"37","author":"May","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_177","first-page":"2395","article-title":"The effect of low dose methotrexate on bone density","volume":"28","author":"Cranney","year":"2001","journal-title":"J. Rheumatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/ard.62.2.186","article-title":"Effect of low dose weekly methotrexate on bone mineral density and bone turnover","volume":"62","author":"Patel","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/s10165-005-0443-5","article-title":"Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: Report of two cases and review of the literature","volume":"16","author":"Kaneko","year":"2006","journal-title":"Mod. Rheumatol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.53.4.224","article-title":"Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate","volume":"53","author":"Veen","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum."},{"key":"ref_183","first-page":"387","article-title":"The risk of hospitalized infection in patients with rheumatoid arthritis","volume":"35","author":"Smitten","year":"2008","journal-title":"J. Rheumatol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1093\/rheumatology\/kep101","article-title":"Methotrexate, rheumatoid arthritis and infection risk: What is the evidence?","volume":"48","author":"Aldridge","year":"2009","journal-title":"Rheumatology"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0049-0172(99)80026-2","article-title":"The incidence of cancer associated with the treatmentof rheumatoid arthritis","volume":"29","author":"Beauparlant","year":"1999","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"BMJ"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0046-8177(94)90295-X","article-title":"Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: Frequency of Epstein-Barr virus and other features associated with immunosuppression","volume":"25","author":"Kamel","year":"1994","journal-title":"Hum. Pathol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0002-9343(99)80160-0","article-title":"Hematologic malignancies and the use of methotrexate in rheumatoid arthritis: A retrospective study","volume":"99","author":"Moder","year":"1995","journal-title":"Am. J. Med."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1172\/JCI111512","article-title":"Ethanol-induced activation of adenine nucleotide turnover. Evidence for a role of acetate","volume":"74","author":"Puig","year":"1984","journal-title":"J. Clin. Investig."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/archinte.1985.00360110105023","article-title":"Pneumonitis complicating low-dose methotrexate therapy in rheumatoid arthritis","volume":"145","author":"Rice","year":"1985","journal-title":"Arch. Intern. Med."},{"key":"ref_192","first-page":"939","article-title":"Pentostatin: An Adenosine Deaminase Inhibitor for the Treatment of Hairy Cell Leukemia","volume":"26","author":"Kane","year":"1992","journal-title":"Ann. Pharm."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2340\/00015555-1720","article-title":"Methotrexate-induced accelerated nodulosis in a patient with rheumatoid arthritis and scleroderma","volume":"94","author":"Motegi","year":"2014","journal-title":"Acta Derm. Venereol."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5414\/CNP64315","article-title":"Is low-dose methotrexate nephrotoxic? Case report and review of the literature","volume":"64","author":"Izzedine","year":"2005","journal-title":"Clin. Nephrol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and Managing Methotrexate Nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/nrrheum.2015.8","article-title":"Rheumatoid arthritis therapy reappraisal: Strategies, opportunities and challenges","volume":"11","author":"Smolen","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2217\/14622416.9.4.439","article-title":"An update on methotrexate pharmacogenetics in rheumatoid arthritis","volume":"9","author":"Ranganathan","year":"2008","journal-title":"Pharmacogenomics"},{"key":"ref_199","first-page":"227","article-title":"Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients","volume":"13","author":"Owen","year":"2013","journal-title":"Pharm. J."},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Qiu, Q., Huang, J., Shu, X., Fan, H., Zhou, Y., and Xiao, C. (2017). Polymorphisms and Pharmacogenomics for the Clinical Efficacy of Methotrexate in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-analysis. Sci. Rep., 7.","DOI":"10.1038\/srep44015"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/FPC.0b013e32833315d1","article-title":"Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis","volume":"19","author":"Dervieux","year":"2009","journal-title":"Pharmacogenet. Genom."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1002\/art.22032","article-title":"Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis","volume":"54","author":"Wessels","year":"2006","journal-title":"Arthritis Rheum."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1002\/art.22640","article-title":"Pharmacogenetics Collaborative Research Group A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis","volume":"56","author":"Wessels","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_204","doi-asserted-by":"crossref","unstructured":"Pastore, S., Stocco, G., Favretto, D., De Iudicibus, S., Taddio, A., d\u2019Adamo, P., Malus\u00e0, N., Addobbati, R., Decorti, G., and Lepore, L. (2015). Genetic determinants for methotrexate response in juvenile idiopathic arthritis. Front Pharm., 6.","DOI":"10.3389\/fphar.2015.00052"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/FPC.0000000000000036","article-title":"Genome-wide analysis of methotrexate pharmacogenomics in rheumatoid arthritis shows multiple novel risk variants and leads for TYMS regulation","volume":"24","author":"Senapati","year":"2014","journal-title":"Pharm. Genom."},{"key":"ref_206","first-page":"356","article-title":"Genome-Wide Data Reveals Novel Genes for Methotrexate Response in a Large Cohort of Juvenile Idiopathic Arthritis Cases","volume":"14","author":"Cobb","year":"2014","journal-title":"Pharm. J."},{"key":"ref_207","first-page":"528","article-title":"Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients","volume":"18","author":"Taylor","year":"2018","journal-title":"Pharm. J."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"3553","DOI":"10.1002\/art.34631","article-title":"Gene Profiling of Chikungunya Virus Arthritis in a Mouse Model Reveals Significant Overlap with Rheumatoid Arthritis","volume":"64","author":"Nakaya","year":"2012","journal-title":"Arthritis Rheum"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6040","DOI":"10.1073\/pnas.1318859111","article-title":"Arthritogenic alphaviral infection perturbs osteoblast function and triggers pathologic bone loss","volume":"111","author":"Chen","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.semarthrit.2018.03.011","article-title":"A systematic review of viral exposures as a risk for rheumatoid arthritis","volume":"48","author":"Kudaeva","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/acr.23519","article-title":"Treatment of Chronic Chikungunya Arthritis with Methotrexate: A Systematic Review","volume":"70","author":"Amaral","year":"2018","journal-title":"Arthritis Care Res."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s10067-017-3766-7","article-title":"Management of chikungunya arthritis","volume":"36","author":"Pereira","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_213","doi-asserted-by":"crossref","unstructured":"Javelle, E., Ribera, A., Degasne, I., Ga\u00fcz\u00e8re, B.A., Marimoutou, C., and Simon, F. (2015). Specific Management of Post-Chikungunya Rheumatic Disorders: A Retrospective Study of 159 Cases in Reunion Island from 2006\u20132012. PLoS Negl. Trop. Dis., 9.","DOI":"10.1371\/journal.pntd.0003603"},{"key":"ref_214","first-page":"83","article-title":"Post-chikungunya chronic arthritis\u2014Our experience with DMARDs over two year follow up","volume":"59","author":"Ganu","year":"2011","journal-title":"J. Assoc. Phys. India"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s10067-016-3429-0","article-title":"Efficacy of combination DMARD therapy vs. hydroxychloroquine monotherapy in chronic persistent chikungunya arthritis: A 24-week randomized controlled open label study","volume":"36","author":"Ravindran","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1007\/s11908-011-0180-1","article-title":"Chikungunya Virus Infection","volume":"13","author":"Simon","year":"2011","journal-title":"Curr. Infect. Dis. Rep."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3201\/eid2103.141397","article-title":"Post-Chikungunya Rheumatoid Arthritis, Saint Martin","volume":"21","author":"Foissac","year":"2015","journal-title":"Emerg. Infect. Dis."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/1874312901610010129","article-title":"A Review of Chikungunya Virus-induced Arthralgia: Clinical Manifestations, Therapeutics, and Pathogenesis","volume":"10","author":"Goupil","year":"2016","journal-title":"Open Rheumatol. J."},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Malvy, D., Ezzedine, K., Mamani-Matsuda, M., Autran, B., Tolou, H., Receveur, M.C., Pistone, T., Rambert, J., Moynet, D., and Mossalayi, D. (2009). Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect. Dis., 9.","DOI":"10.1186\/1471-2334-9-200"},{"key":"ref_220","doi-asserted-by":"crossref","unstructured":"Taylor, A., Sheng, K.C., Herrero, L.J., Chen, W., Rulli, N.E., and Mahalingam, S. (2013). Methotrexate Treatment Causes Early Onset of Disease in a Mouse Model of Ross River Virus-Induced Inflammatory Disease through Increased Monocyte Production. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0071146"},{"key":"ref_221","doi-asserted-by":"crossref","unstructured":"Bedoui, Y., Giry, C., Jaffar-Bandjee, M.C., Selambarom, J., Guiraud, P., and Gasque, P. (2018). Immunomodulatory drug methotrexate used to treat patients with chronic inflammatory rheumatisms post-chikungunya does not impair the synovial antiviral and bone repair responses. PLoS Negl. Trop. Dis., 12.","DOI":"10.1371\/journal.pntd.0006634"},{"key":"ref_222","doi-asserted-by":"crossref","unstructured":"Miner, J.J., Cook, L.E., Hong, J.P., Smith, A.M., Richner, J.M., Shimak, R.M., Young, A.R., Monte, K., Poddar, S., and Crowe, J.E. (2017). Therapy with CTLA4-Ig and an antiviral monoclonal antibody controls chikungunya virus arthritis. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aah3438"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.autrev.2008.07.025","article-title":"Hepatitis C virus-related arthritis","volume":"8","author":"Palazzi","year":"2008","journal-title":"Autoimmun. Rev."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/rheumatology\/keh668","article-title":"Rheumatological manifestations of hepatitis C: Incidence in a rheumatology and non-rheumatology setting and the effect of methotrexate and interferon","volume":"44","author":"Nissen","year":"2005","journal-title":"Rheumatology"},{"key":"ref_225","first-page":"363","article-title":"Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis","volume":"18","author":"Mok","year":"2000","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.11451","article-title":"Hepatitis C and methotrexate","volume":"49","author":"Kujawska","year":"2003","journal-title":"Arthritis Care Res."},{"key":"ref_227","doi-asserted-by":"crossref","unstructured":"Chen, Y.L., Jing, J., Mo, Y.Q., Ma, J.D., Yang, L.J., Chen, L.F., Zhang, X., Yan, T., Zheng, D.H., and Pessler, F. (2018). Presence of hepatitis B virus in synovium and its clinical significance in rheumatoid arthritis. Arthritis Res., 20.","DOI":"10.1186\/s13075-018-1623-y"},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/1529-0131(200102)44:2<339::AID-ANR51>3.0.CO;2-Q","article-title":"Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient","volume":"44","author":"Ito","year":"2001","journal-title":"Arthritis Rheum."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/ard.62.7.686","article-title":"Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate","volume":"62","author":"Ostuni","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12072-014-9597-6","article-title":"Long-term use of methotrexate does not result in hepatitis B reactivation in rheumatologic patients","volume":"9","author":"Laohapand","year":"2015","journal-title":"Hepatol. Int."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Tang, K.T., Chen, Y.H., Lin, C.H., and Chen, D.Y. (2016). Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis C. Sci. Rep., 6.","DOI":"10.1038\/srep33104"},{"key":"ref_232","doi-asserted-by":"crossref","unstructured":"Tang, K.T., Hung, W.T., Chen, Y.H., Lin, C.H., and Chen, D.Y. (2016). Methotrexate is not associated with increased liver cirrhosis in a population-based cohort of rheumatoid arthritis patients with chronic hepatitis B. Sci. Rep., 6.","DOI":"10.1038\/srep22387"},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/BOR.0b013e32832c9d04","article-title":"Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era","volume":"21","author":"Nguyen","year":"2009","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jbspin.2013.01.002","article-title":"Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: Three case studies from Saudi Arabia","volume":"80","author":"Almoallim","year":"2013","journal-title":"Jt. Bone Spine"},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/OARRR.S87312","article-title":"Rheumatoid arthritis in patients with HIV: Management challenges","volume":"8","author":"Carroll","year":"2016","journal-title":"Open Access Rheumatol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1001\/archderm.1987.01660360050012","article-title":"Acquired Immunodeficiency Syndrome\u2014Associated Psoriasis and Reiter\u2019s Syndrome","volume":"123","author":"Duvic","year":"1987","journal-title":"Arch. Derm."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.jaad.2009.03.047","article-title":"Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation","volume":"62","author":"Menon","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/S0190-9622(94)70175-X","article-title":"The use of methotrexate for treatment of psoriasis in patients with HIV infection","volume":"31","author":"Maurer","year":"1994","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_239","unstructured":"Masson, C., Chennebault, J.M., and Leclech, C. (1995). Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?. J. Rheumatol., 22."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/20\/5023\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:01Z","timestamp":1760189101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/20\/5023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,10]]},"references-count":239,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2019,10]]}},"alternative-id":["ijms20205023"],"URL":"https:\/\/doi.org\/10.3390\/ijms20205023","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,10]]}}}